Repare to receive a $125M up front, ~$1.2B in clinical, regulatory, commercial & sales milestones including ~$55M in near-term fees along with royalties. Roche will be responsible for developing camonsertib & expand its development into additional tumors & multiple combination studies
If regulatory approval is granted in the US, Repare can opt-in to a 50/50 US co-development & profit share including US co-promotion. If the option is exercised, Repare will continue to receive milestones & Ex-US royalties
Repare’s SNIPRx platform is designed to develop precision therapies in patients whose tumors have ≥1 genomic alteration & selectively target those tumors in patients with clinical benefit from resulted product candidates
Ref: Businesswire | Image: Roche
